Podcast
Questions and Answers
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in preventing the development of diabetic nephropathy in hypertensive patients with type 2 diabetes and persistent microalbuminuria.
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in preventing the development of diabetic nephropathy in hypertensive patients with type 2 diabetes and persistent microalbuminuria.
True
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 1 diabetes and persistent microalbuminuria.
The IRMA Il trial evaluated the effectiveness of the angiotensin-II-receptor antagonist irbesartan in hypertensive patients with type 1 diabetes and persistent microalbuminuria.
False
The IRMA Il trial focused on the use of irbesartan in normotensive patients with type 2 diabetes.
The IRMA Il trial focused on the use of irbesartan in normotensive patients with type 2 diabetes.
False
